Navigation Links
Questcor Reports Fourth Quarter and Full Year 2012 Results
Date:2/26/2013

share-based compensation expense, depreciation and amortization expense, and impairment of intangibles. Non-GAAP earnings for the comparable period of 2011 were $1.27 per diluted common share.

Research and Development Programs Questcor's continued strong financial performance has enabled the company to increase investment in research programs to further clarify the potential immune-modulating properties of Acthar and identify Acthar mechanisms of action applicable to other inflammatory and auto-immune diseases with high unmet need. Questcor currently has approximately 35 company-sponsored clinical and pre-clinical research projects underway. Key company-sponsored clinical programs are in process in the following disease states:

  • Lupus: Enrollment is underway in a company-sponsored multi-site Phase 4 clinical trial to evaluate the efficacy and safety of daily Acthar administration over a 6-month period in patients with persistently active lupus.
  • Idiopathic Membranous Nephropathy: Enrollment continues in a company-sponsored Phase 4 trial in idiopathic membranous nephropathy. Patients enrolled in this study are refractory, or non-responsive, to current standard therapies or have relapsed after partial remission on current standard therapies.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Amyotrophic Lateral Sclerosis (ALS): Questcor is in discussions with the U.S. Food and Drug Administration (FDA) to commence clinical trials of Acthar for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.  The company expects to file an Investigational New Drug application (I
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    2. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    3. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    4. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    5. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    6. Questcor Comments on Insurance Policy Bulletin
    7. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    8. Questcor Pharmaceuticals to Present at Investor Conferences in September
    9. Questcor Reports Second Quarter Financial Results
    10. Questcor to Report Second Quarter Results on July 24, 2012
    11. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)...  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... be participating in the Morgan Stanley 2014 Global Healthcare ... York, New York , on Tuesday, September 9, ... Zimmer, will be presenting at 9:10 a.m. Eastern Time.  ... will join Mr. Dvorak for the Q&A session. ...
    (Date:8/27/2014)... 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) has ... (FDA) to initiate a Phase 1/2a clinical trial of ... cord injury.  The approved trial follows the successful completion ... and is designed to assess safety and activity of ... spinal cord injuries, the first targeted indication for AST-OPC1 ...
    (Date:8/26/2014)... Malaysia , Aug. 27, 2014 ... health insurance are fuelling the demand for medical ... the rise of medical tourism, the inflow of ... increasing. The market will continue its steady ascent ... to age-related and non-communicable diseases, compelling significant investments ...
    Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4
    (Date:8/27/2014)... Neil Haley, the Total Tutor host of the Simply ... about the importance of capacity to grow a business. , ... and is now a 5 Star Ambassador, Vi Millionaire, and ... titled "The Playful and Powerful Warrior Within You!" and holds ... out for over 1000 days straight. He is also ...
    (Date:8/27/2014)... York, NY (PRWEB) August 27, 2014 Overcoming ... failure, he finally found his niche. The Women’s Radio Network, ... Armstrong for his continued support and dedication to the WRNW1 ... be able to have such a positive atmosphere.” After KC ... on Sirius XM of the Howard Stern show, “Howard 100 ...
    (Date:8/27/2014)... 2014 A recently published study ... of time in correcting coagulopathy to prevent permanent injury ... of anticoagulants and examines medical conditions alleged to be ... although anticoagulants have been approved by the FDA to ... are also known to affect the consistency of the ...
    (Date:8/27/2014)... (PRWEB) August 27, 2014 The use ... quality of life and may eliminate the need for ... During a recent AllMed webinar, Dr. Zanhua Yi, board ... related to determining medical necessity of erythropoiesis-stimulating agents (ESAs) ... (CKD). , The U.S. Food and Drug Administration (FDA) ...
    (Date:8/27/2014)... August 27, 2014 iHire was ... as the “Most Creative Workplace” in Frederick, a ... Places to Work Awards. , Held at the ... is a joint partnership between the Frederick County ... Development, Frederick County Business Development and Retention, and ...
    Breaking Medicine News(10 mins):Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:iHire Named Most Creative Workplace in Frederick, MD 2
    ... March 3, 2008 The International AIDS Vaccine Initiative ... Fund, a new funding mechanism that will identify and ... AIDS vaccine research field. This initial project will apply ... the size of a small coin, which has the ...
    ... a new genetic risk factor for coeliac disease, have, ... implicated in causing the condition. The team, lead by ... and The London School of Medicine and Dentistry, have ... now know, four of these are also predisposing factors ...
    ... March 2 Therap Services announces the,release of version ... applications. Therap version 7.2 will feature,new forms such as ... module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) form in ... 7.2 include: -- Behavior Plan and Behavior Event ...
    ... Incontinence, dropped organs not just a function of age, study ... women in the United States have one or more pelvic ... disorders, says a Kaiser Permanente study. , Frequent urge to ... of such disorders. , The study of 4,000 women (80 ...
    ... Md. and ST. PAUL, Minn., Feb. 29 /PRNewswire-USNewswire/,-- ... Society &,Family Services, application for full Hague Accreditation ... This achievement of Hague,Accreditation demonstrates CHSFS, commitment to ... and abroad., The Hague Convention on Protection ...
    ... OAKLAND, Calif., Feb. 29 California,s,largest nonprofit hospital ... negotiations Thursday covering 15,000 hospital,workers across California., ... of negotiations underway and,continue their joint efforts to ... services across the state. In 2004, Catholic Healthcare,West ...
    Cached Medicine News:Health News:IAVI and VaxDesign partner to develop a clinical trial in a test tube for AIDS vaccines 2Health News:Scientists uncover further steps leading to celiac disease 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:Pelvic Floor Disorders Affect 1 in 3 Women 2Health News:Children's Home Society & Family Services Achieves Full Hague Accreditation 2Health News:Catholic Healthcare West and SEIU Begin Negotiations for 15,000 Hospital Workers 2
    Inquire...
    ... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
    ... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
    The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
    Medicine Products: